ArticleNature immunology2012
Induction and molecular signature of pathogenic TH17 cells.
Article in Nature immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 722 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
722 citing papers in PubMed, 1,155 citations in OpenAlex.
- Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.Nature medicine · 2024Trial
- Metabolic stress-activated endothelial STING rewires the sinusoidal immune niche to promote MASLD progression.The Journal of clinical investigation · 2026Article
- Exacerbation of inflammatory bone loss in TET2-driven clonal hematopoiesis.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Unconventional role of hydroxymethylglutaryl-CoA synthase 1 in driving pathogenic TScience advances · 2026Article
- A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state.Immunity · 2026Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- A microRNA atlas of CD4+ T cell subsets in experimental autoimmune encephalomyelitis identifies regulators of disease pathogenesis.PLoS biology · 2026Article
- Concomitant psoriasis may be associated with a more severe disease course in inflammatory bowel disease: a retrospective cohort study.Scientific reports · 2026Article
- MARBL: A Live-Cell Method for Profiling Bioenergetic Heterogeneity by Noncanonical Methionine Labeling of the Cell Surface Proteome.bioRxiv : the preprint server for biology · 2026Article
- Role of MAPK Pathways in the Pathogenesis of Vitiligo.Current issues in molecular biology · 2026Review
- Systemic Cytokine Patterns and Histologic Disease Spectrum in Inflammatory Bowel Disease.Current issues in molecular biology · 2026Article
- Contextualizing TNature reviews. Immunology · 2026Review
- Spatial transcriptomics atlas of inflammatory bowel disease to guide implementation in research consortiums and clinical trials.Nature communications · 2026Article
- Systemic Immune Signatures of Endoscopic-Histologic Discordance in Inflammatory Bowel Disease: A Pilot Study.Journal of clinical medicine · 2026Article
- Effect of the intestinal microbiota on TSeminars in immunopathology · 2026Review
- Aiolos and Eos drive distinct human TH17 functional states.Cellular and molecular life sciences : CMLS · 2026Article
- Inflammation drives TGFβ1 activation via the αvβ6 integrin-mechanotransduction pathway in human skin.iScience · 2026Article
- Enhanced HIF-1α cooperation by a human RORγt mutant potentiates Th17 pathogenicity.Cell reports · 2026Article
- NMI promotes the secretion of IL-17 and exacerbates psoriasis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2026Review
662 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
Interleukin 17 (IL-17)-producing helper T cells (T(H)17 cells) are often present at the sites of tissue inflammation in autoimmune diseases, which has led to the conclusion that T(H)17 cells are main drivers of autoimmune tissue injury. However, not all T(H)17 cells are pathogenic; in fact, T(H)17 cells generated with transforming growth factor-β1 (TGF-β1) and IL-6 produce IL-17 but do not readily induce autoimmune disease without further exposure to IL-23. Here we found that the production of TGF-β3 by developing T(H)17 cells was dependent on IL-23, which together with IL-6 induced very pathogenic T(H)17 cells. Moreover, TGF-β3-induced T(H)17 cells were functionally and molecularly distinct from TGF-β1-induced T(H)17 cells and had a molecular signature that defined pathogenic effector T(H)17 cells in autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.